SG Americas Securities LLC acquired a new position in shares of LeMaitre Vascular Inc (NASDAQ:LMAT) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 11,782 shares of the medical instruments supplier’s stock, valued at approximately $394,000. SG Americas Securities LLC owned 0.06% of LeMaitre Vascular at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in the business. BlackRock Inc. grew its position in LeMaitre Vascular by 2.9% in the first quarter. BlackRock Inc. now owns 2,331,839 shares of the medical instruments supplier’s stock valued at $84,483,000 after acquiring an additional 65,903 shares during the period. Conestoga Capital Advisors LLC grew its position in LeMaitre Vascular by 8.9% in the second quarter. Conestoga Capital Advisors LLC now owns 1,392,591 shares of the medical instruments supplier’s stock valued at $46,624,000 after acquiring an additional 113,705 shares during the period. Epoch Investment Partners Inc. grew its position in LeMaitre Vascular by 3.9% in the first quarter. Epoch Investment Partners Inc. now owns 771,339 shares of the medical instruments supplier’s stock valued at $27,945,000 after acquiring an additional 28,627 shares during the period. Northern Trust Corp grew its position in LeMaitre Vascular by 1.8% in the first quarter. Northern Trust Corp now owns 249,251 shares of the medical instruments supplier’s stock valued at $9,030,000 after acquiring an additional 4,465 shares during the period. Finally, Bank of New York Mellon Corp grew its position in LeMaitre Vascular by 3.0% in the second quarter. Bank of New York Mellon Corp now owns 246,444 shares of the medical instruments supplier’s stock valued at $8,251,000 after acquiring an additional 7,177 shares during the period. 79.75% of the stock is currently owned by institutional investors.
NASDAQ:LMAT traded up $0.29 during mid-day trading on Friday, hitting $28.22. The company had a trading volume of 222,174 shares, compared to its average volume of 151,980. LeMaitre Vascular Inc has a fifty-two week low of $26.45 and a fifty-two week high of $41.28. The firm has a market capitalization of $748.16 million, a price-to-earnings ratio of 32.81, a PEG ratio of 2.42 and a beta of 0.63.
LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Friday, October 5th. The medical instruments supplier reported $0.21 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.21. The company had revenue of $24.17 million for the quarter, compared to analyst estimates of $26.06 million. LeMaitre Vascular had a return on equity of 19.49% and a net margin of 21.09%. As a group, sell-side analysts expect that LeMaitre Vascular Inc will post 1.07 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 6th. Stockholders of record on Tuesday, November 20th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.99%. The ex-dividend date of this dividend is Monday, November 19th. LeMaitre Vascular’s dividend payout ratio is currently 32.56%.
LMAT has been the topic of several research analyst reports. BidaskClub cut LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Saturday, September 8th. Roth Capital upgraded LeMaitre Vascular from a “neutral” rating to a “buy” rating and decreased their target price for the stock from $39.00 to $34.00 in a report on Monday, October 8th. Canaccord Genuity decreased their target price on LeMaitre Vascular from $40.00 to $32.00 and set a “hold” rating on the stock in a report on Monday, October 8th. Lake Street Capital cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, October 5th. Finally, Zacks Investment Research cut LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Wednesday, September 26th. Two analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $35.63.
In related news, Chairman George W. Lemaitre sold 14,180 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, August 22nd. The stock was sold at an average price of $37.61, for a total value of $533,309.80. Following the sale, the chairman now owns 3,118,266 shares of the company’s stock, valued at approximately $117,277,984.26. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO George W. Lemaitre sold 22,000 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, July 25th. The shares were sold at an average price of $37.26, for a total value of $819,720.00. Following the completion of the sale, the chief executive officer now directly owns 3,085,291 shares in the company, valued at approximately $114,957,942.66. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 97,506 shares of company stock worth $3,608,759. 20.30% of the stock is currently owned by insiders.
About LeMaitre Vascular
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Recommended Story: Initial Public Offering (IPO)
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.